CT/MRI LI-RADS 2018版主要特征组合的诊断效能:个体参与者数据Meta分析
该系统评价与个体参与者数据Meta分析纳入46项研究、6765例患者共7500个肝脏观察灶,计算CT/MRI LI-RADS 2018版主要特征组合诊断HCC的阳性预测值。LR-3、LR-4、LR-5的合并PPV分别为58.28%、80.82%、95.81%,同一类别内多数主要特征组合PPV无差异,支持当前分类,但LR-3至LR-5中有5个组合的PPV与所在类别合并值不同。
要点
- LR-5合并PPV为95.81%(95%CI:91.06,98.09),LR-4为80.82%(95%CI:71.04,87.86),LR-3为58.28%(95%CI:44.00,71.29)。
- 同一LI-RADS类别内多数主要特征组合PPV与同类其他组合无差异(LR-3 P值范围.17-.73,LR-4 .10至>.99,LR-5 .08至>.99)。
- 5个组合PPV偏离所在类别合并值:LR-3无廓清APHE且<20 mm无其他主要特征为14.81%,APHE 10-19 mm无其他主要特征为68.33%;LR-4无APHE且≥20 mm伴强化包膜为50.81%;LR-5 APHE 10-19 mm伴阈值增长为74.40%,APHE≥20 mm伴阈值增长为82.35%。
核心结论
- 同一CT/MRI LI-RADS类别内多数主要特征组合对高危患者HCC的PPV相似,但LR-3至LR-5中有5个组合的PPV与所在类别合并值不同。
研究设计与样本
- 系统评价与个体参与者数据Meta分析,检索Medline、Embase、Cochrane Central和Scopus 2014年1月至2023年2月发表的文献,纳入46项研究、6765例患者(平均年龄59岁±10.69〔SD〕,男性75%〔5081/6765〕,年龄范围18-93岁)、7500个肝脏观察灶。
诊断标准与关键数值
- LR-3合并PPV为58.28%(95%CI:44.00,71.29),LR-4为80.82%(95%CI:71.04,87.86),LR-5为95.81%(95%CI:91.06,98.09)。LR-3中无廓清APHE且测量<20 mm无其他主要特征者PPV为14.81%(95%CI:6.35,30.85;P<.001),APHE测量10-19 mm无其他主要特征者为68.33%(95%CI:53.94,79.90;P=.01)。LR-4中无APHE且测量≥20 mm伴强化包膜者为50.81%(95%CI:28.92,72.39;P=.009)。LR-5中APHE测量10-19 mm伴阈值增长者为74.40%(95%CI:51.06,89.00;P<.001),APHE测量≥20 mm伴阈值增长者为82.35%(95%CI:57.29,94.20;P=.02)。
临床应用与阅片要点
- 阅片报告LI-RADS类别时可参考各主要特征组合的PPV;LR-3中无廓清APHE且<20 mm无其他主要特征者PPV为14.81%,APHE 10-19 mm无其他主要特征者为68.33%;LR-4中无APHE且≥20 mm伴强化包膜者为50.81%;LR-5中APHE 10-19 mm伴阈值增长者为74.40%,APHE≥20 mm伴阈值增长者为82.35%。
局限性
- 80%的研究(37/46)至少一个领域存在高偏倚风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background The CT/MRI Liver Imaging Reporting and Data System (LI-RADS) diagnostic algorithm classifies liver observations in patients with high-risk hepatocellular carcinoma (HCC) using imaging features. However, data regarding the diagnostic performance of specific LI-RADS major feature combinations is limited. Purpose To conduct a systematic review and individual participant data (IPD) meta-analysis to establish the positive predictive values (PPVs) of LI-RADS major feature combinations using CT/MRI LI-RADS version 2018 in patients at risk for HCC. Materials and Methods Medline, Embase, Cochrane Central, and Scopus were searched for studies published from January 2014 to February 2023. Studies reporting HCC percentages for LI-RADS categories in patients at high risk for HCC were included. A one-stage random-effects IPD meta-analysis was used to calculate the PPV for HCC diagnosis and 95% CIs of major feature combinations. Wald test was used to compare combinations. Risk of bias (RoB) was assessed using Quality Assessment of Diagnostic Accuracy Studies 2, known as QUADAS-2 (protocol: https://osf.io/ah5kn). Results Forty-six studies including 6765 patients (mean age, 59 years ± 10.69 [SD]; 75% male patients [5081 of 6765]; age range, 18-93 years) with 7500 liver observations were analyzed. High RoB in at least one domain was found in 80% of studies (37 of 46). The pooled PPV estimate for major feature combinations was 58.28% in LR-3 (95% CI: 44.00, 71.29), 80.82% in LR-4 (95% CI: 71.04, 87.86), and 95.81% in LR-5 (95% CI: 91.06, 98.09). The majority of LI-RADS major feature combinations had PPVs that did not differ from others within the same category, supporting the current categorization (P value ranges: LR-3, .17-.73; LR-4, .10 to >.99; LR-5, .08 to >.99). Notably, five major feature combinations differed from the pooled PPV of the LR category. LR-3 was lower without nonrim arterial phase hyperenhancement (APHE) measuring smaller than 20 mm without additional major features (14.81%; 95% CI: 6.35, 30.85; P < .001), and higher with APHE measuring 10-19 mm without additional major features (68.33%; 95% CI: 53.94, 79.90; P = .01). LR-4 was lower without APHE measuring 20 mm or larger with enhancing capsule (50.81%; 95% CI: 28.92, 72.39; P = .009). LR-5 was lower with APHE measuring 10-19 mm with threshold growth (74.40%; 95% CI: 51.06, 89.00; P < .001), and with APHE measuring 20 mm or larger with threshold growth (82.35%; 95% CI: 57.29, 94.20; P = .02). Conclusion This meta-analysis showed that most major feature combinations in the same CT/MRI LI-RADS category had similar PPVs for HCC in patients at high risk for HCC, with the exception of five combinations within LR-3 through LR-5. © RSNA, 2025 Supplemental material is available for this article. See also the editorial by Johnson in this issue.
引用
- Adamo RG, van der Pol CB, Alabousi M, et al. Diagnostic Performance of CT/MRI LI-RADS Version 2018 Major Feature Combinations: Individual Participant Data Meta-Analysis. Radiology. 2025. PMID: 40492918. doi:10.1148/radiol.243450
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。